GlassScriptPhysician profile
Brenda M Cupp
NPI 1366530628
$4,492.52
in general payments reported to CMS, 2019-2025
23 companies · $662 in 2025
The $662 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $13.89 · 2023: $428 · 2024: $3,263 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,223 · Travel and Lodging: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,222.65 |
| Travel and Lodging | $1,130.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,042.14 | 2024-2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $519.58 | 2023-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $408.32 | 2023-2025 | |
| Abbott Laboratories | $327.84 | 2021-2025 | Cardiomems, Jot Dx, Ensite Precision |
| Astrazeneca Pharmaceuticals LP | $277.42 | 2022-2025 | Farxiga, Lokelma, Brilinta |
| Pfizer INC. | $150.67 | 2024-2025 | |
| Amgen INC. | $138.95 | 2023-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.91 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $75.42 | 2023 | Verquvo |
| Teva Pharmaceuticals USA, INC. | $71.95 | 2023-2024 | Uzedy |
| Alnylam Pharmaceuticals INC. | $53.93 | 2025 | Amvuttra |
| Novo Nordisk INC | $48.15 | 2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $35.41 | 2023 | Xarelto |
| Scpharmaceuticals INC. | $33.64 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $31.92 | 2024 | Uptravi, Opsumit |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $30.24 | 2023-2025 | |
| Organogenesis INC. | $23.31 | 2025 | Puraply Wound Matrix |
| Atricure, INC. | $19.84 | 2024 | |
| Kestra Medical Technology Services, INC. | $19.03 | 2025 | Assure Wcd |
| Kiniksa Pharmaceuticals, LTD. | $16.75 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $16.70 | 2024 | |
| Sanofi-Aventis U.S. LLC | $14.93 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $13.47 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenda Cupp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.